Figure 2
Blockade of LT/LIGHT inhibits late systemic and local proinflammatory cytokines release induced by HSV-1 infection.
(a) Rag1–/– mice (n = 7 to 9/group) were injected with 1 × 107 pfu of HSV-1 and treated with LTβR-Ig or control protein as Fig. 1A. On day 7 p.i., cytokine levels of IL-6, MCP-1, TNF and IFN-γ in the serum were determined by CBA. Data are pooled from two independent experiments. (b, c) On day 7 p.i., cytokine levels in the homogenate of spinal cord (b) and brain (c) were determined. n = 4 to 5/group. Data are representative of two independent experiments. (d) Rag1–/– mice (n = 4 to 11/group) were infected with 2 × 106 pfu of HSV-1 and treated with indicated antibody or protein to block in vivo cytokine signaling. TNFR-Ig or LTβR-Ig was administrated at 100 ug/mice on day-1 and day 5 p.i.; Anti-IL-6 was administrated at 400 ug/mice every 3 days starting from day -1. Data are representative of two independent experiments. Uninfected, mice without infection; HSV+ Ctr Ig, infected mice with control protein treatment; HSV+ LTβR-Ig, infected mice with LTβR-Ig treatment. Statistical analysis for a, b, c. was by unpaired t test. Error bar represents SEM, *p < 0.05, **p < 0.01, ***p < 0.001; ns, no significant difference. d. was by log rank test.
